Armata Pharmaceuticals Q2 2024 Earnings Report

Armata Pharmaceuticals EPS Results

• Actual EPS: -$0.65
• Consensus EPS: -$0.52
• Beat/Miss: Missed by -$0.13
• One Year Ago EPS: N/A

Armata Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Armata Pharmaceuticals Announcement Details

• Quarter: Q2 2024
• Date: 8/13/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens. Its lead program, AP-PA02, has advanced into early-stage clinical evaluation, while additional efforts focus on preclinical development of therapies for diabetic foot infections and anthrax prophylaxis. The company collaborates with U.S. government agencies on biodefense and public health initiatives, underscoring the potential utility of its phage platform in addressing both emerging and established bacterial threats.

Founded in 2017 and headquartered in Horsham, Pennsylvania, Armata Pharmaceuticals serves the U.S. market with an eye toward global expansion as clinical data emerge. The company is led by Chairman and Chief Executive Officer George Eliopoulos, whose experience in infectious disease drug development guides Armata’s strategic partnerships and research efforts. Through its innovative biologics approach, Armata aims to deliver safer and more effective treatments for patients facing life-threatening bacterial infections.